Dr. Ruxandra Teslo argues America's biotech problem isn't the science, it's how slowly we learn from humans: "This is going to be more and more of a bottleneck as science advances especially in oncology. It's not just that we don't have enough clinical trials and they are expensive. This has become worse and worse throughout the years." "The article is particularly focused on these phase one clinical trials. These are the trials where you first take a new drug into humans for the first time.…